

Table SI. Impact of itch overall and by physician-judged disease severity

EU5 and US total	Overall		Mild at sampling		Moderate at sampling		Severe at sampling	
	Patient-reported (PSC)	Carer-reported (CSC)	Patient-reported (PSC)	Carer-reported (CSC)	Patient-reported (PSC)	Carer-reported (CSC)	Patient-reported (PSC)	Carer-reported (CSC)
In the last week, frequency of itching due to psoriasis?*, n (%)	N=657	N=347	N=524	N=276	N=121	N=64	N=12	N=7
Never	226 (34.4)	89 (25.6)	213 (40.6)	83 (30.1)	12 (9.9)	5 (7.8)	1 (8.3)	1 (14.3)
Sometimes, usually, or all of the time	180 (27.4)	120 (34.6)	94 (17.9)	75 (27.2)	77 (63.6)	41 (64.1)	9 (75.0)	4 (57.1)
How much has itch impacted*: n (%)								
School/work	N=516	N=300	N=391	N=234	N=114	N=60	N=11	N=6
Not at all	254 (49.2)	143 (47.7)	223 (57.0)	125 (53.4)	29 (25.4)	17 (28.3)	2 (18.2)	1 (16.7)
Quite a bit, a lot, or a huge amount	55 (10.7)	40 (13.3)	18 (4.6)	17 (7.3)	31 (27.2)	20 (33.3)	6 (54.5)	3 (50.0)
Sleep	N=517	N=301	N=391	N=235	N=115	N=60	N=11	N=6
Not at all	223 (43.1)	118 (39.2)	201 (51.4)	107 (45.5)	21 (18.3)	10 (16.7)	1 (9.1)	1 (16.7)
Quite a bit, a lot, or a huge amount	67 (13.0)	50 (16.6)	25 (6.4)	25 (10.6)	34 (29.6)	21 (35.0)	8 (72.7)	4 (66.7)
Physical activities	N=516	N=299	N=390	N=233	N=115	N=60	N=11	N=6
Not at all	244 (47.3)	148 (49.5)	211 (54.1)	128 (54.9)	32 (27.8)	20 (33.3)	1 (9.1)	0 (0)
Quite a bit, a lot, or a huge amount	79 (15.3)	44 (14.7)	37 (9.5)	22 (9.4)	36 (31.3)	19 (31.7)	6 (54.5)	3 (50.0)
Social activities	N=516	N=300	N=390	N=234	N=115	N=60	N=11	N=6
Not at all	245 (47.5)	156 (52.0)	212 (54.4)	135 (57.7)	32 (27.8)	21 (35.0)	1 (9.1)	0 (0)
Quite a bit, a lot, or a huge amount	72 (14.0)	41 (13.7)	27 (6.9)	24 (10.3)	37 (32.2)	14 (23.3)	8 (72.7)	3 (50.0)

*Answer to question also included 'once in a while'. EU and US combined data. CSC, carer self-completion; EU5, 5 key European countries; N, number of patients/carers with available data; n, number of patients responding per group; PSC, patient self-completion questionnaire; US, United States

Table SII. Physician-, patient- and carer-reported reasons for treatment dissatisfaction, overall and by physician-judged severity

Reasons for treatment dissatisfaction, n (%)	Overall	Mild at sampling	Moderate at sampling	Severe at sampling
Physician-reported (PRF)	n=221	n=93	n=112	n=16
Complete skin clearance not achieved	86 (38.9)	40 (43.0)	42 (37.5)	4 (25.0)
Efficacy decrease/not sustained over time (secondary loss of response)	55 (24.9)	17 (18.3)	34 (30.4)	4 (25.0)
Treatment is not working quickly enough	52 (23.5)	20 (21.5)	28 (25.0)	4 (25.0)
Patient dissatisfied	48 (21.7)	16 (17.2)	28 (25.0)	4 (25.0)
It does not alleviate flares	38 (17.2)	9 (9.7)	24 (21.4)	5 (31.3)
Patient-reported (PSC)	n=166	n=94	n=65	n=7
It hasn't completely cleared all my skin	118 (71.1)	67 (71.3)	46 (70.8)	5 (71.4)
People can still see my psoriasis	66 (39.8)	41 (43.6)	24 (36.9)	1 (14.3)
I'm worried I may need it forever	54 (32.5)	27 (28.7)	24 (36.9)	3 (42.9)
It isn't working quickly enough	54 (32.5)	20 (21.3)	30 (46.2)	4 (57.1)
I think there are better treatments	36 (21.7)	11 (11.7)	24 (36.9)	1 (14.3)
Carer-reported (CSC)	n=111	n=65	n=41	n=5
It hasn't completely cleared all my child's skin	81 (73.0)	47 (72.3)	29 (70.7)	5 (100.0)
We/they are worried they may need the treatment forever	45 (40.5)	27 (41.5)	17 (41.5)	1 (20.0)
People can still see my child's psoriasis	40 (36.0)	26 (40.0)	14 (34.2)	0 (0)
It isn't working quickly enough	39 (35.1)	18 (27.7)	19 (46.3)	2 (40.0)
My child doesn't like the way it feels on their skin (sticky/greasy)	29 (26.1)	15 (23.1)	12 (29.3)	2 (40.0)

Reasons for treatment dissatisfaction (overall in EU5 and US) were pre-specified in the PRF (physician), PSC (patient) and CSC (carer) and multiple answers were allowed. Data are represented as proportion (%) of the overall population of physicians, patients and carers selecting each particular answer (multiple answers were allowed). Only the five most frequently answered reasons are displayed. Only physician data in which there were matched patient-level data (PSC or CSC) are reported.

CSC, carer self-completion questionnaire; EU5, 5 key European countries; n, number of patients with available data; PRF, Patient Record Form; PSC, patient self-completion questionnaire.

Table SIII. Physician, patient and carer reported treatment goals before starting current treatment regimen

Treatment goals, n (%)	Physician (n=1017)	Patient (n=666)	Carer (n=351)
Relieves itching	654 (64.3)	457 (68.6)	272 (77.5)
Works quickly	537 (52.8)	446 (67.0)	211 (60.1)
Works for a long time	527 (51.8)	340 (51.1)	204 (58.1)
Clears 100% of skin	360 (35.4)	409 (61.4)	211 (60.1)
Almost clear skin	470 (46.2)	234 (35.1)	149 (42.5)
Easy administration schedule	279 (27.4)	272 (40.8)	179 (51.0)
Is safe to take	372 (36.6)	173 (26.0)	161 (45.9)
Relieves pain	315 (31.0)	228 (34.2)	128 (36.5)
Relieves scaling/flaking	417 (41.0)	345 (51.8)	193 (55.0)
Helps alleviate redness/discoloration	313 (30.8)	254 (38.1)	159 (45.3)

Treatment goals (overall in EU5 and US) were pre-specified in the PRF (physician), PSC (patient) and CSC (carer) and multiple answers were allowed. Data are represented as proportion (%) of the overall population of physicians, patients and carers selecting each particular answer (multiple answers were allowed). Only the ten most frequently answered treatment goals are displayed. Only physician data in which there were matched patient-level data (PSC or CSC) are reported.

CSC, carer self-completion questionnaire; EU5, 5 key European countries; n, number of patients with available data; PSC, patient self-completion questionnaire; US, United States.